RT Journal Article
SR Electronic
T1 Effectiveness and waning of protection with different SARS-CoV-2 primary and booster vaccines during the Delta pandemic wave in 2021 in Hungary (HUN-VE 3 study)
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2022.04.14.22273898
DO 10.1101/2022.04.14.22273898
A1 Vokó, Zoltán
A1 Kiss, Zoltán
A1 Surján, György
A1 Surján, Orsolya
A1 Barcza, Zsófia
A1 Wittmann, István
A1 Molnár, Gergő Attila
A1 Nagy, Dávid
A1 Müller, Veronika
A1 Bogos, Krisztina
A1 Nagy, Péter
A1 Kenessey, István
A1 Wéber, András
A1 Polivka, Lőrinc
A1 Pálosi, Mihály
A1 Szlávik, János
A1 Rokszin, György
A1 Müller, Cecília
A1 Szekanecz, Zoltán
A1 Kásler, Miklós
YR 2022
UL http://medrxiv.org/content/early/2022/04/18/2022.04.14.22273898.abstract
AB Background In late 2021, the pandemic wave was dominated by the Delta SARS-CoV-2 variant in Hungary. Booster vaccines were offered starting from August 2021.Methods The nationwide HUN-VE 3 study examined the effectiveness and durability of primary immunization and single booster vaccinations on SARS-CoV-2-related infection, hospitalization and mortality during the Delta wave.Results The study population included 8,087,988 individuals aged 18–100 years at the beginning of the pandemic. During the Delta wave, after adjusting for age, sex, calendar day, and chronic diseases, vaccine effectiveness (VE) of primary vaccination against registered SARS-CoV-2 infection was between 11% to 77% and 18% to 79% 14–120 days after primary immunization in the 16–64 and 65–100 years age cohort respectively, while it decreased to close to zero in the younger age group and around 40% or somewhat less in the elderly after 6 months for almost all vaccine types. In the population aged 65–100 years, we found high, 88.1%–92.5% adjusted effectiveness against Covid-19 infection after the Pfizer-BioNTech, and 92.2%–95.6% after the Moderna booster dose, while Sinopharm and Janssen booster doses provided 26.5%–75.3% and 72.9%–100.0% adjusted VE, respectively. Adjusted VE against Covid-19 related hospitalization was high within 14–120 days for Pfizer-BioNTech: 76.6%, Moderna: 83.8%, Sputnik-V: 78.3%, AstraZeneca: 73.8%, while modest for Sinopharm: 45.7% and Janssen: 26.4%. The waning of protection against Covid-19 related hospitalization was modest and booster vaccination with mRNA vaccines or the Janssen vaccine increased adjusted VE up to almost 100%, while the Sinopharm booster dose proved to be less effective. VE against Covid-19 related death after primary immunization was high or moderate: for Pfizer-BioNTech: 81.5%, Moderna: 93.2%, Sputnik-V: 100.0%, AstraZeneca: 84.8%, Sinopharm: 58.6%, Janssen: 53.3%). VE against this outcome also showed moderate decline over time, while booster vaccines restored effectiveness up to almost 100%, except for the Sinopharm booster.Conclusions The HUN-VE 3 study demonstrated waning VE with all vaccine types for all examined outcomes during the Delta wave and confirmed the outstanding benefit of booster vaccination with the mRNA or Janssen vaccines. This is the first study to provide comparable effectiveness results for six different booster types during the Delta pandemic wave.Competing Interest StatementZsofia Barcza of Syntesia Medical Communications Ltd. received payment for medical writing support from the National Public Health Center of Hungary. Zoltan Kiss is employed by MSD Pharma Hungary Ltd., too. However, this provides no relevant conflict of interest for the current research. At the time the study was performed, M.K served as the minister of human resources. The ministry includes the secretariat for health.Funding StatementThe Center for Health Technology Assessment of the Semmelweis University participated in the project on a contractual basis made with the Ministry of Human Resources of Hungary and received funding. Zsofia Barcza of Syntesia Medical Communications Ltd. received payment for medical writing support from the National Public Health Center of Hungary.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The study was approved by the Central Ethical Committee of Hungary (OGYEI/10296-1/2022 and IV/1722- 1/2022/EKU).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe datasets generated for this study can be found in the MedRxiv repository. Further inquiries can be directed to the corresponding author.